STAT3 and prostate neoplasm: Another justification for potentially targeting STAT3 in nonmetastatic CRPC is the fact that inhibition of STAT3 might prevent treatment-induced neuroendocrine-like prostate tumor phenotype, also termed as t-NEPC.